MarketPeel
Insider Trading Intelligence
JJ

Jonathan C. Javitt

NRXP
CHIEF SCIENTIST · NRX PHARMACEUTICALS, INC. · CIK 0001303782
FILING MIX · LIFETIME90%/10%
BUYS
9
SELLS
1
TOTAL VALUE
$6.40M
COMPANIES
1
ACTIVE SINCE
May 2021
HOLDINGS NOW
125,000
AVG SELL PX
$1.00
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jonathan C. Javitt, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+83.33%+2.34%+1.09%+1.25%+8.13%
14d6+33.33%-3.71%-2.60%-1.11%-4.26%
30d6+33.33%+18.89%-3.22%+22.11%-1.21%
60d6+66.67%+24.42%-0.15%+24.57%+23.57%
90d6+100.00%+1.53%-0.34%+1.87%+8.52%
180d6+100.00%+68.23%+5.45%+62.78%+78.77%
1y6+66.67%-7.97%+16.12%-24.09%-16.23%
2y6(1 pending)+20.00%-36.26%+44.48%-80.73%-66.23%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NRXP · 125,000 shares · as of Apr 9, 2025
03,337,2496,674,49910,011,74813,348,9972022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
FLOW · 9 buys / 1 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
125,000125,000Apr 9, 2025Sep 10, 2025View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASE
Chairman and Chief Scientist
40,000$1.17$46.8K84,634Dec 17, 2024Dec 17, 2024View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASE
Chief Scientist
100,000$0.33$33.0K446,332Aug 23, 2023Aug 24, 2023View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASE
Chief Scientist
200,000$0.32$64.4K346,332Aug 22, 2023Aug 22, 2023View →
NRXP
NRX PHARMACEUTICALS, INC.
SALE
400,000$1.00$400.0K12,899,997Dec 7, 2022Dec 9, 2022View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASE
Chief Scientist
100,000$58.00$5.80M146,332Jun 1, 2022Jun 2, 2022View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASE
Chief Scientist
100,000$0.58$58.0K146,332Jun 1, 2022Jun 2, 2022View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
46,33246,332May 24, 2021Jun 10, 2021View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,422,0001,422,000May 24, 2021Jun 10, 2021View →
NRXP
NRX PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
13,348,99713,348,997May 24, 2021Jun 10, 2021View →
Other insiders · NRXP
Loading peer insiders…
About this filer
CIK 0001303782
ROLE
Chief Scientist
PRIMARY
NRXP
COMPANIES
1
ACTIVE SINCE
May 2021
MARKETPEEL · /INSIDER/0001303782DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback